Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks upgraded to Overweight on 2025 pipeline at JPMorgan
- Zymeworks upgraded to Overweight from Neutral at JPMorgan
- Zymeworks Advances Oncology and Expands Therapeutic Reach
- Zymeworks hosts R&D day highlighting continued clinical progress
- Zymeworks to Showcase Innovations at Investor Conferences